Contact SCGE
Your email
Message
Send
SCGE Consortium Home
About SCGE TCDC
Contact Us
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency
NCTID
NCT06422351
(View at clinicaltrials.gov)
Description
This is an open-label Phase II trial to evaluate the efficacy of a hematopoietic cell-based gene therapy for patients with Pyruvate Kinase Deficiency (PKD).
(Show More)
Development Status
Active
Indication
Pyruvate Kinase Deficiency
Disease Ontology Term
DOID:0111077
Compound Name
RP-L301
Sponsor
Rocket Pharmaceuticals Inc.
Funder Type
Industry
Recruitment Status
Not yet recruiting
Enrollment Count
10
Results Posted
Not Available
Therapy Information
Target Gene/Variant
PKLR
Therapy Type
Gene transfer
Therapy Route
Ex-vivo
Mechanism of Action
Functional gene replacement
Route of Administration
Intravenous
Drug Product Type
Viral vector
Target Tissue/Cell
Delivery System
Viral transduction
Vector Type
PGK-coPRK-WPRE
Editor Type
none
Dose 1
Dose range: 2.3E6 - 6.5E6 transduced CD34+ cells/kg
Dose 2
Dose 3
Dose 4
Dose 5
Study Record Dates
Current Stage
Phase2
Submit Date
2024-05-15
Completion Date
2029-01
Last Update
2024-05-22
Participation Criteria
Eligible Age
8 Years - 55 Years
Standard Ages
Child, Adult
Sexes Eligible for Study
ALL
Locations
No.of Trial Sites
3
Locations
United States,Spain
Regulatory Information
Has US IND
True
FDA Designations
Fast Track, Orphan Drug Designation, Regenerative Medicine Advanced Therapy
Recent Updates
Resources/Links
Clinical Publications
(Abstract #4) Gene Therapy for Adult and Pediatric Patients with Severe Pyruvate Kinase Deficiency: Results from a Global Study of RPL301 - ASGCT 2024
News and Press Releases
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Preclinical Publications
Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency
Protocol
(Abstract) RP-L301, a Lentiviral-Mediated Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase 2 Clinical Trial Design - ASH 2024
Related NCTID
Phase 1: NCT04105166